How many clinical trials are tracked of valganciclovir?

19 trials are tracked, 6 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

valganciclovir

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of valganciclovir

19 trials tracked of valganciclovir: 11 in phase 3 or 4 and 6 with published results. The most-cited published study has 184 citations.

19Trials tracked

11Phase 3 & 4

0Recruiting

6With published results

Phase distribution

Phase 4 5 Phase 3 6 Phase 2 6 Phase 1 1 Other / NA 1

Phase 3 Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) Completed · 184 cited
Phase 4 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Completed · 170 cited
Phase 3 Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir Completed · 76 cited
Phase 3 A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants Completed · 53 cited
Phase 4 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed · 4 cited
Phase 4 Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Completed

Show 13 more trials

Phase 4 A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls Completed
Phase 4 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed
Phase 3 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Completed
Phase 3 Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation Completed
Phase 3 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed
Phase 2 Letermovir for CMV Prevention After Lung Transplantation Completed
Phase 2 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Completed
Phase 2 ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation Completed
Phase 2 Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients Completed
Phase 2 Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation Completed
Phase 2 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss Completed
Phase 1 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF) Completed
N/A Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.